|
|
CHI's Structure-Based Drug Design
概要
GPCR的构造模拟
蛋白质交互作用位置之解析
计算机模拟蛋白质设计
有效活性化合物(hits)及先导化合物(lead)之优化
配体结合(ligand binding)中受体弹性之分析
嵌合(docking)与筛选(screening)的挑战
実験成果
案例学习
相关活动
在Structure-Based Drug Design 国际会议召开前,于同一场所另有一个
Protein Kinase Targets国际会议 ,在此建议一并注册参加。
预定发表主题
- AILERON Therapeutics
- ARIAD Pharmaceuticals Inc.
- AstraZeneca R&D Mölndal
- Bristol-Myers Squibb
- California Institute of Technology
- Centocor Research and Development
- Chemical Computing Group Inc.
- Elan Pharmaceuticals
- Harvard Medical School
- Locus Pharmaceuticals
- Lundbeck Research (Denmark) Merck Research Laboratories
- National Center for Scientifi c Research
(CNRS)
- NIH, NIDDK
- Novartis
- OSI Pharmaceuticals
- Pfizer Global Research and Development
- Schrodinger, Inc.
- SGX Pharmaceuticals
- SimBioSys
- University of York
- Vernalis
|
语言选择
|